Lisata Therapeutics President and CEO Dave Mazzo joined Steve Darling from Proactive to share news the company has announced a global collaboration and license agreement with Kuva Labs, a subsidiary of Mi2 Holdings, to enhance cancer imaging technologies.
Under the agreement, Kuva Labs will integrate Lisata’s iRGD cyclic peptide product candidate, certepetide, with its NanoMark platform to develop advanced magnetic resonance (MR) imaging agents. This combination aims to enable safe, non-invasive, and precise detection of solid tumor cancers.
Kuva will oversee all research, development, and commercialization costs for NanoMark, while Lisata will supply certepetide. The partnership includes an upfront license fee, substantial milestone payments, and royalty agreements, offering significant value creation for both companies.
This collaboration positions Lisata and Kuva at the forefront of innovative diagnostic solutions, potentially transforming the landscape of solid tumor cancer detection.